Fosaprepitant and aprepitant: An update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

Core Evidence

Volumn 5, Issue , 2010, Pages 77-90

  Langford, Patrick ^a   Chrisp, Paul ^b  

^a Prime Medica Ltd   (United Kingdom)

^b Core Medical Publishing ^*  (United Kingdom)

Author keywords

Aprepitant; Chemotherapy; Fosaprepitant; Nausea; Vomiting

Indexed keywords

ANTHRACYCLINE; APREPITANT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DEXAMETHASONE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOSAPREPITANT; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; MITOXANTRONE; NAVELBINE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PALONOSETRON; SEROTONIN ANTAGONIST; SUBSTANCE P; WARFARIN;

ALCOHOL ABUSE; AREA UNDER THE CURVE; BIOEQUIVALENCE; CHEMOTHERAPY INDUCED EMESIS; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79953836604     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S6012     Document Type: Review

References (38)

1. Chrisp P. Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core Evidence. 2007;2:15-30. (Pubitemid 47109410)
2. Aguilar EA, Figueiras MC, Cortes-Funes H, et al. Clinical practice guidelines on antiemetics in oncology. Expert Rev Anticancer Ther. 2005;5:963-972. (Pubitemid 43033786)
3. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94-102.
4. Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002;69:609-610, 612, 615-617.
5. Herrstedt J, Aapro MS, Roila F, Kataja VV; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol. 2005;16(Suppl 1):i77-i79.
6. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13:85-96. (Pubitemid 40558163)
7. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994. (Pubitemid 29415258)
8. Viale PH. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. Clin J Oncol Nurs. 2005;9:77-84.
9. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119. (Pubitemid 46606178)
10. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
11. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4:403-408. (Pubitemid 44541016)
12. Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab Dispos. 1999;27:1367-1373.
13. Hale JJ, Mills SG, MacCoss M, et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem. 2000;43:1234-1241. (Pubitemid 30173749)
14. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47:834-840.
15. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947. (Pubitemid 46630595)
16. Herrstedt J, Roila F; ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2008;19(Suppl 2):ii110-ii112.
17. MASCC (Multinational Association for Supportive Care in Cancer). Antiemetic guideline consensus. 2008. Available at: http://data.memberclicks. com/site/mascc/MASCC-Guidelines-Update.pdf Accessed August 20, 2008.
18. NCCN (National Comprehensive Cancer Network). Clinical practice guidelines in oncology. Antiemesis. v.3. 2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf. Accessed August 20, 2008.
19. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112:2080-2087. (Pubitemid 351574085)
20. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113:529-535.
21. Oechsle K, Müller MR, Hartmann JT, Kanz L, Bokemeyer C. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie. 2006;29:557-561.
22. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835-842.
23. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002;94:3032-3041. (Pubitemid 34547705)
24. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830. (Pubitemid 46179473)
25. Lordick F, Ehlken B, Ihbe-Heffinger A, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43:299-307. (Pubitemid 46123990)
26. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health. 2007;10:23-31. (Pubitemid 46161092)
27. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21:4105-4111. (Pubitemid 46606177)
28. NICE (National Institute for Health and Clinical Excellence). Measuring effectiveness and cost effectiveness: the QALY. 2007. Available at: http://www.nice.org.uk/newsroom/features/ measuringeffectivenessandcosteffectivenesstheqaly.jsp Accessed August 20, 2008.
29. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press. 1996.
30. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31. (Pubitemid 27224092)
31. Goldman L. Cost-effectiveness in a flat world-can ICDs help the United States get rhythm? N Engl J Med. 2005;353:1513-1515.
32. Annemans L, Strens D, Lox E, Petit C, Malonne H. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008;16:905-915.
33. Herrstedt J, Muss HB, Warr DG, et al; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548-1555.
34. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-1006. (Pubitemid 43778994)
35. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526-536. (Pubitemid 38444561)
36. Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncol. 2005;2:127-132. (Pubitemid 40396846)
37. Bell CF, Foley KA, Pelissier JM, Hu HX, Markson LE, Berger ML. Cost consequence model: assessing the use of aprepitant vs. standard anti-emetic therapy in cancer patients undergoing highly emetogenic chemotherapy. Support Care Cancer. 2004;12. Abstract 17.
38. Anon. Ivemend Prescribing Information. Available at: http://www.merck. com/product/usa/pi-circulars/e/emend-iv/emend-iv-pi.pdf. Accessed August 20, 2008.